Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2- advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial

W. Janni, E. Alba, T. Bachelot, S. Diab, M. Gil-Gil, TJ. Beck, L. Ryvo, R. Lopez, M. Tsai, FJ. Esteva, PZ. Auñón, Z. Kral, P. Ward, P. Richards, TJ. Pluard, S. Sutradhar, M. Miller, M. Campone,

. 2018 ; 169 (3) : 469-479. [pub] 20180205

Language English Country Netherlands

Document type Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial

Persistent link   https://www.medvik.cz/link/bmc19012867
E-resources Online Full text

NLK ProQuest Central from 1997-01-01 to 1 year ago
Medline Complete (EBSCOhost) from 2005-01-01 to 1 year ago
Health & Medicine (ProQuest) from 1997-01-01 to 1 year ago
Family Health Database (ProQuest) from 1997-01-01 to 1 year ago
Public Health Database (ProQuest) from 1997-01-01 to 1 year ago

Links

PubMed 29404806
DOI 10.1007/s10549-017-4658-x
Knihovny.cz E-resources

PURPOSE: The phase 3 MONALEESA-2 study demonstrated that addition of ribociclib (RIB) to letrozole (LET) significantly improved progression-free survival (PFS) in patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC). Here, we evaluated duration of response (DoR), tumor shrinkage, PFS by treatment-free interval (TFI), and health-related quality of life (HRQoL). METHODS: Postmenopausal women (N = 668) with HR+ , HER2- ABC and no prior systemic therapy for ABC were randomized to RIB (600 mg/day; 3 weeks on/1 week off) plus LET (2.5 mg/day; continuous) or placebo (PBO) plus LET. Primary end point was PFS; HRQoL was the secondary end point; DoR was exploratory end point and PFS by TFI was post hoc analysis. RESULTS: Of 501 pts with measurable disease and confirmed complete or partial response, median DoR was 26.7 months (95% CI, 24.0-NR) in the RIB arm versus 18.6 months (95% CI, 14.8-23.1) in the PBO arm. At 8 weeks, more pts in the RIB arm (32%) versus the PBO arm (17%) experienced best percentage change ≥ 60%. The average pain reduction was greater in the RIB arm (26%) versus the PBO arm (15%). PFS benefit was seen with RIB vs PBO, irrespective of TFI. CONCLUSION: RIB plus LET versus PBO plus LET is associated with earlier and more durable tumor response, greater degree of tumor shrinkage and pain reduction, and PFS benefit irrespective of TFI. These data further support RIB plus LET as a first-line treatment option for postmenopausal women with HR+ , HER2- ABC.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19012867
003      
CZ-PrNML
005      
20190411093822.0
007      
ta
008      
190405s2018 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s10549-017-4658-x $2 doi
035    __
$a (PubMed)29404806
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Janni, Wolfgang $u University of Ulm, Helmholtzstraße 18, 89081, Ulm, Germany. Wolfgang.Janni@uniklinik-ulm.de.
245    10
$a First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2- advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial / $c W. Janni, E. Alba, T. Bachelot, S. Diab, M. Gil-Gil, TJ. Beck, L. Ryvo, R. Lopez, M. Tsai, FJ. Esteva, PZ. Auñón, Z. Kral, P. Ward, P. Richards, TJ. Pluard, S. Sutradhar, M. Miller, M. Campone,
520    9_
$a PURPOSE: The phase 3 MONALEESA-2 study demonstrated that addition of ribociclib (RIB) to letrozole (LET) significantly improved progression-free survival (PFS) in patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC). Here, we evaluated duration of response (DoR), tumor shrinkage, PFS by treatment-free interval (TFI), and health-related quality of life (HRQoL). METHODS: Postmenopausal women (N = 668) with HR+ , HER2- ABC and no prior systemic therapy for ABC were randomized to RIB (600 mg/day; 3 weeks on/1 week off) plus LET (2.5 mg/day; continuous) or placebo (PBO) plus LET. Primary end point was PFS; HRQoL was the secondary end point; DoR was exploratory end point and PFS by TFI was post hoc analysis. RESULTS: Of 501 pts with measurable disease and confirmed complete or partial response, median DoR was 26.7 months (95% CI, 24.0-NR) in the RIB arm versus 18.6 months (95% CI, 14.8-23.1) in the PBO arm. At 8 weeks, more pts in the RIB arm (32%) versus the PBO arm (17%) experienced best percentage change ≥ 60%. The average pain reduction was greater in the RIB arm (26%) versus the PBO arm (15%). PFS benefit was seen with RIB vs PBO, irrespective of TFI. CONCLUSION: RIB plus LET versus PBO plus LET is associated with earlier and more durable tumor response, greater degree of tumor shrinkage and pain reduction, and PFS benefit irrespective of TFI. These data further support RIB plus LET as a first-line treatment option for postmenopausal women with HR+ , HER2- ABC.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a aminopyridiny $x aplikace a dávkování $7 D000631
650    _2
$a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $x terapeutické užití $7 D000971
650    _2
$a nádorové biomarkery $7 D014408
650    _2
$a nádory prsu $x farmakoterapie $x metabolismus $x patologie $7 D001943
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a letrozol $x aplikace a dávkování $7 D000077289
650    _2
$a lidé středního věku $7 D008875
650    _2
$a metastázy nádorů $7 D009362
650    _2
$a staging nádorů $7 D009367
650    _2
$a puriny $x aplikace a dávkování $7 D011687
650    _2
$a kvalita života $7 D011788
650    _2
$a receptor erbB-2 $x metabolismus $7 D018719
650    _2
$a receptory pro estrogeny $x metabolismus $7 D011960
650    _2
$a receptory progesteronu $x metabolismus $7 D011980
650    _2
$a výsledek terapie $7 D016896
650    _2
$a mladý dospělý $7 D055815
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Alba, Emilio $u Hospital Universitario Virgen de la Victoria, IBIMA, Málaga, Spain.
700    1_
$a Bachelot, Thomas $u Centre Léon Bérard, Lyon, France.
700    1_
$a Diab, Sami $u Rocky Mountain Cancer Centers, Aurora, CO, USA.
700    1_
$a Gil-Gil, Miguel $u Institut Català d'Oncologia, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
700    1_
$a Beck, Thaddeus J $u Highlands Oncology Group, Fayetteville, AR, USA.
700    1_
$a Ryvo, Larisa $u Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
700    1_
$a Lopez, Rafael $u Hospital Clínico Universitario e Instituto de Investigación Santiago-CIBERONC, A Coruña, Spain.
700    1_
$a Tsai, Michaela $u Minnesota Oncology, Minneapolis, MN, USA.
700    1_
$a Esteva, Francisco J $u Perlmutter Cancer Center at New York University Langone Health, New York, NY, USA.
700    1_
$a Auñón, Pilar Zamora $u Hospital Universitario La Paz, Madrid, Spain.
700    1_
$a Kral, Zdenek $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic.
700    1_
$a Ward, Patrick $u Oncology Hematology Care, Kenwood, OH, USA.
700    1_
$a Richards, Paul $u Oncology Hematology Associates of Southwest Virginia, Roanoke, VA, USA.
700    1_
$a Pluard, Timothy J $u Saint Luke's Health System, Kansas City, MO, USA.
700    1_
$a Sutradhar, Santosh $u Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
700    1_
$a Miller, Michelle $u Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
700    1_
$a Campone, Mario $u Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France.
773    0_
$w MED00009361 $t Breast cancer research and treatment $x 1573-7217 $g Roč. 169, č. 3 (2018), s. 469-479
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29404806 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190405 $b ABA008
991    __
$a 20190411093839 $b ABA008
999    __
$a ok $b bmc $g 1392177 $s 1051172
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 169 $c 3 $d 469-479 $e 20180205 $i 1573-7217 $m Breast cancer research and treatment $n Breast Cancer Res Treat $x MED00009361
LZP    __
$a Pubmed-20190405

Find record

Citation metrics

Archiving options